* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:21:43 ON 12 OCT 2007

=> file reg
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:21:52 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 OCT 2007 HIGHEST RN 950420-07-2
DICTIONARY FILE UPDATES: 11 OCT 2007 HIGHEST RN 950420-07-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\xanthine.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss fam
'SSS' IS NOT VALID HERE
For additional help, enter "HELP SEARCH".

=> s l1 sam fam
SAMPLE SEARCH INITIATED 15:22:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED        1 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               0 TO        0

L2             0 SEA FAM SAM L1

=> s l1 fam full
FULL SEARCH INITIATED 15:22:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       58 TO ITERATE

100.0% PROCESSED       58 ITERATIONS                                 12 ANSWERS
SEARCH TIME: 00.00.01

L3            12 SEA FAM FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    67.70      67.91

FILE 'CAPLUS' ENTERED AT 15:22:32 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 12 Oct 2007  VOL 147 ISS 17
FILE LAST UPDATED: 11 Oct 2007  (20071011/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4             87 L3

=> d ti au so py 1-10

L4   ANSWER 1 OF 87  CAPLUS  COPYRIGHT 2007 ACS on STN
```

TI Amphetamine and the adenosine A2A antagonist KW-6002 enhance the effects of conditional temporal probability of a stimulus in rats
AU O'Neill, Martin; Brown, Verity J.
SO Behavioral Neuroscience (2007), 121(3), 535-542
CODEN: BENEDJ; ISSN: 0735-7044
PY 2007

L4 ANSWER 2 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI The effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats
AU O'Neill, Martin; Brown, Verity J.
SO Neurobiology of Learning and Memory (2007), 88(1), 75-81
CODEN: NLMEFR; ISSN: 1074-7427
PY 2007

L4 ANSWER 3 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Compounds for the treatment of auricular fibrillation
IN Franco Fernandez, Rafael; Ciruela Alferez, Francisco; Lluis Biset, Carmen; Mueller, Christa; Cinca Cuscullola, Joan; Hove-Madsen, Leif
SO PCT Int. Appl., 33pp.
CODEN: PIXXD2
PY 2007
2007
2007

L4 ANSWER 4 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists
AU Yang, Ming; Soohoo, Daniel; Soelaiman, Sandriyana; Kalla, Rao; Zablocki, Jeff; Chu, Nancy; Leung, Kwan; Yao, Lina; Diamond, Ivan; Belardinelli, Luiz; Shryock, John C.
SO Naunyn-Schmiedeberg's Archives of Pharmacology (2007), 375(2), 133-144
CODEN: NSAPCC; ISSN: 0028-1298
PY 2007

L4 ANSWER 5 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Compositions and methods for inhibiting neurodegeneration
IN Kalb, Robert Gordon; Mojsilovic-Petrovic, Jelena
SO U.S. Pat. Appl. Publ., 36pp.
CODEN: USXXCO
PY 2007

L4 ANSWER 6 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice
AU Xiao, Danqing; Bastia, Elena; Xu, Yue-Hang; Benn, Caroline L.; Cha, Jang-Ho J.; Peterson, Tracy S.; Chen, Jiang-Fan; Schwarzschild, Michael A.
SO Journal of Neuroscience (2006), 26(52), 13548-13555
CODEN: JNRSDS; ISSN: 0270-6474
PY 2006

L4 ANSWER 7 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches
AU Richardson, Christine M.; Gillespie, Roger J.; Williamson, Douglas S.; Jordan, Allan M.; Fink, Alexandra; Knight, Antony R.; Sellwood, Daniel M.; Misra, Anil
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(23), 5993-5997
CODEN: BMCLE8; ISSN: 0960-894X
PY 2006

L4 ANSWER 8 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease

AU Kalda, Anti; Yu, Liqun; Oztas, Emin; Chen, Jiang-Fan
SO Journal of the Neurological Sciences (2006), 248(1-2), 9-15
CODEN: JNSCAG; ISSN: 0022-510X
PY 2006

L4 ANSWER 9 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. [Erratum to document cited in CA145:411022]
AU Mojsilovic-Petrovic, Jelena; Jeong, Goo-Bo; Crocker, Amanda; Arneja, Amrita; David, Samuel; Russell, David S.; Kalb, Robert G.
SO Journal of Neuroscience (2006), 26(40), No pp. given
CODEN: JNRSDS; ISSN: 0270-6474
PY 2006

L4 ANSWER 10 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors
AU Mojsilovic-Petrovic, Jelena; Jeong, Goo-Bo; Crocker, Amanda; Arneja, Amrita; David, Samuel; Russell, David; Kalb, Robert G.
SO Journal of Neuroscience (2006), 26(36), 9250-9263
CODEN: JNRSDS; ISSN: 0270-6474
PY 2006

=> d ti au so py 11-25

L4 ANSWER 11 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Assay development and screening of a serine/threonine kinase in an on-chip mode using caliper nanofluidics technology
AU Perrin, Dominique; Fremaux, Christele; Scheer, Alexander
SO Journal of Biomolecular Screening (2006), 11(4), 359-368
CODEN: JBISF3; ISSN: 1087-0571
PY 2006

L4 ANSWER 12 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
IN Grzelak, Michael; Hunter, John; Pond, Annamarie; Varty, Geoffrey
SO U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 234,644.
CODEN: USXXCO
PY 2006
2004
2005
2005
2005
2005
2006
2005
2006
2007

L4 ANSWER 13 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preventive and/or therapeutic agent for drug dependence
IN Kase, Junya; Kurokawa, Masako; Shiozaki, Shizuo; Seno, Naoki
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
PY 2006

L4 ANSWER 14 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders
IN Grzelak, Michael; Hunter, John; Pond, Annamarie; Varty, Geoffrey
SO U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 738,906.
CODEN: USXXCO

PY 2006
2004
2005
2005
2005
2005
2006
2005
2006
2007

L4 ANSWER 15 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Effects of the A2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo
AU Harper, L. K.; Beckett, S. R.; Marsden, C. A.; McCreary, A. C.; Alexander, S. P. H.
SO Pharmacology, Biochemistry and Behavior (2006), 83(1), 114-121
CODEN: PBBHAU; ISSN: 0091-3057
PY 2006

L4 ANSWER 16 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Parkinson's disease
AU Nagai, Masahiro; Nomoto, Masahiro
SO Rinsho Yakuri (2005), 36(6), 273-276
CODEN: RIYADS; ISSN: 0388-1601
PY 2005

L4 ANSWER 17 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Antagonizing an adenosine A2A receptor to amelioriate one or more components of addictive behavior
IN Diamond, Ivan F.; Gordon, Adrienne S.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
PY 2006
2007
2006
2006
2006
2007

L4 ANSWER 18 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI The effect of the adenosine A2A antagonist KW-6002 on motor and motivational processes in the rat
AU O'Neill, Martin; Brown, Verity J.
SO Psychopharmacology (Berlin, Germany) (2006), 184(1), 46-55
CODEN: PSCHDL; ISSN: 0033-3158
PY 2006

L4 ANSWER 19 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice
AU Kachroo, Anil; Orlando, Lianna R.; Grandy, David K.; Chen, Jiang-Fan; Young, Anne B.; Schwarzschild, Michael A.
SO Journal of Neuroscience (2005), 25(45), 10414-10419
CODEN: JNRSDS; ISSN: 0270-6474
PY 2005

L4 ANSWER 20 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Treatment of Parkinson's disease: what' on the horizon?
AU Wu, Stacy S.; Frucht, Steven J.
SO CNS Drugs (2005), 19(9), 723-743
CODEN: CNDREF; ISSN: 1172-7047
PY 2005

L4 ANSWER 21 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preventive and/or therapeutic agent for disease accompanied by chronic muscle/skeleton pain
IN Kase, Hiroshi; Takahashi, Isami; Kunori, Shunji; Kobayashi, Minoru; Shiozaki, Shizuo; Shirakura, Shiro
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
PY 2005
2005
2007
2007

L4 ANSWER 22 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists
AU Pinna, Annalisa; Wardas, Jadwiga; Simola, Nicola; Morelli, Micaela
SO Life Sciences (2005), 77(26), 3259-3267
CODEN: LIFSAK; ISSN: 0024-3205
PY 2005

L4 ANSWER 23 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Adenosine A2A receptor antagonists for parkinson's disease: rationale, therapeutic potential and clinical experience
AU Hauser, Robert A.; Schwarzschild, Michael A.
SO Drugs & Aging (2005), 22(6), 471-482
CODEN: DRAGE6; ISSN: 1170-229X
PY 2005

L4 ANSWER 24 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
IN Goldman, Steven A.; Nedergaard, Maiken; Lin, Jane
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
PY 2005
2005

L4 ANSWER 25 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Xanthin derivative hydrates, and pharmaceutical compositions containing the same
IN Sato, Norie; Kita, Shoji; Aoki, Noboru; Uchimura, Tatsuo
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
PY 2005

=> d abs l4 25

L4 ANSWER 25 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
AB The invention provides a hydrate of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione (I) or its salt for use as an adenosine A2 receptor antagonist for treatment of related disease, wherein the hydrate form of I shows improved bioavailability as compared with anhydride form of I or its salt. For example, a tablet containing I hexahydrate 20, lactose 143.4, potato starch 30, hydroxypropyl cellulose 6, magnesium stearate 0.6 mg was formulated.

=> d ti au so py 26-40 l4

L4 ANSWER 26 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Drug for treating migraine
IN Takeuchi, Megumi; Takayama, Makoto; Shirakura, Shiro; Kase, Hiroshi
SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2
PY 2005
2005
2006
2007

L4 ANSWER 27 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Xanthine derivatives and salts and compositions for preventing and/or treating higher brain dysfunction
IN Kase, Hiroshi; Nakagawa, Yutaka; Shiozaki, Shizuo; Kobayashi, Minoru; Toki, Shinichiro; Seno, Naoki; Ikeda, Ken
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
PY 2005
2005
2005
2006
2007
2007
2007
2006
2007

L4 ANSWER 28 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease
AU Jenner, Peter
SO Expert Opinion on Investigational Drugs (2005), 14(6), 729-738
CODEN: EOIDER; ISSN: 1354-3784
PY 2005

L4 ANSWER 29 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia
AU Lundblad, M.; Usiello, A.; Carta, M.; Hakansson, K.; Fisone, G.; Cenci, M. A.
SO Experimental Neurology (2005), 194(1), 66-75
CODEN: EXNEAC; ISSN: 0014-4886
PY 2005

L4 ANSWER 30 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Method of stabilizing diarylvinylene compound
IN Uchida, Akihiro; Ishikawa, Yasuhiro; Ueno, Yasuhiko; Kaji, Kiichiro; Aimoto, Masaharu; Kaneko, Naoki
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
PY 2005
2005
2005
2006
2006
2006

L4 ANSWER 31 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI medicinal compositions containing adenosine A2A receptor antagonists and dopamine agonists
IN Kase, Hiroshi; Kobayashi, Minoru; Shiozaki, Shizuo; Mori, Akihisa; Senoo, Naoki
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
PY 2005

L4 ANSWER 32 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse
AU Pierri, Mette; Vaudano, Elisabetta; Sager, Thomas; Englund, Ulrica

SO Neuropharmacology (2005), 48(4), 517-524
CODEN: NEPHBW; ISSN: 0028-3908
PY 2005

L4 ANSWER 33 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Medicinal compositions containing adenosine A2A receptor antagonists and other antidepressants
IN Kase, Hiroshi; Kobayashi, Minoru; Shiozaki, Shizuo; Mori, Akihisa; Seno, Naoki
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
PY 2005
2005
2006
2006
2006

L4 ANSWER 34 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Solid pharmaceutical compositions containing xanthine derivatives and crystalline cellulose
IN Uchida, Akihiro; Ishikawa, Yasuhiro; Ueno, Yasuhiko; Kaji, Kiichiro; Tottori, Tuneaki
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
PY 2005
2005
2005
2006
2006
2006

L4 ANSWER 35 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis of alkyne derivatives of a novel triazolopyrazine as A2A adenosine receptor antagonists
AU Yao, Gang; Haque, Serajul; Sha, Li; Kumaravel, Gnanasambandam; Wang, Joy; Engber, Thomas M.; Whalley, Eric T.; Conlon, Patrick R.; Chang, Hexi; Kiesman, William F.; Petter, Russell C.
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(3), 511-515
CODEN: BMCLE8; ISSN: 0960-894X
PY 2005

L4 ANSWER 36 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Antiepileptic agent
IN Ichikawa, Shunji; Takashima, Chiemi; Imma, Hironori; Shimada, Junichi
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
PY 2005
2005
2006
2006

L4 ANSWER 37 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI A method using an adenosine A2A receptor antagonist for treating an anxiety disorder
IN Kase, Hiroshi; Seno, Naoki; Shiozaki, Shizuo; Kobayashi, Minoru; Kase, Junya
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
PY 2004
2004
2004
2006
2006
2006

2006
2006
2006
2005
2007

L4 ANSWER 38 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione
IN Kuroda, Kazutoshi; Aoki, Noboru; Ochiai, Toshiro; Uchida, Akihiro; Ishikawa, Yasuhiro; Kigoshi, Makoto; Hayakawa, Eiji; Asanome, Kazuki
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
PY 2004
2004
2004
2006
2006
2006
2007

L4 ANSWER 39 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Novel Diamino Derivatives of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as Potent and Selective Adenosine A2a Receptor Antagonists
AU Vu, Chi B.; Pan, Deborah; Peng, Bo; Kumaravel, Gnanasambandam; Smits, Glenn; Jin, Xiaowei; Phadke, Deepali; Engber, Thomas; Huang, Carol; Reilly, Jennifer; Tam, Stacy; Grant, Donna; Hetu, Gregg; Petter, Russell C.
SO Journal of Medicinal Chemistry (2005), 48(6), 2009-2018
CODEN: JMCMAR; ISSN: 0022-2623
PY 2005

L4 ANSWER 40 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI A method using (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine for treating behavioral disorders
IN Shiozaki, Shizuo; Shimada, Junichi; Kase, Hiroshi; Shindo, Mayumi
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
PY 2004
2004
2004
2004
2005
2005
2006
2006
2006
2005
2006

=> d ti so py au 80-87

L4 ANSWER 80 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Therapeutic agent for neural degeneration
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
PY 1999
1999
2001
2000
2006
2006
2006

2006
2001
2003
2004
2004
2006
2006
IN Shimada, Junichi; Kurokawa, Masako; Ikeda, Ken; Susuki, Fumio; Kuwana, Yoshihisa

L4 ANSWER 81 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Adenosine A2A receptors modify motor function in MPTP-treated common marmosets
SO NeuroReport (1998), 9(12), 2857-2860
CODEN: NERPEZ; ISSN: 0959-4965
PY 1998
AU Kanda, Tomoyuki; Tashiro, Tomomi; Kuwana, Yoshihisa; Jenner, Peter

L4 ANSWER 82 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
SO Annals of Neurology (1998), 43(4), 507-513
CODEN: ANNED3; ISSN: 0364-5134
PY 1998
AU Kanda, Tomoyuki; Jackson, Michael J.; Smith, Lance A.; Pearce, Ronald K. B.; Nakamura, Joji; Kase, Hiroshi; Kuwana, Yoshihisa; Jenner, Peter

L4 ANSWER 83 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Adenosine A2A antagonists with potent anti-cataleptic activity
SO Bioorganic & Medicinal Chemistry Letters (1997), 7(18), 2349-2352
CODEN: BMCLE8; ISSN: 0960-894X
PY 1997
AU Shimada, Junichi; Koike, Nobuaki; Nonaka, Hiromi; Shiozaki, Shizuo; Yanagawa, Koji; Kanda, Tomoyuki; Kobayashi, Hiroyuki; Ichimura, Michio; Nakamura, Joji; Kase, Hiroshi; Suzuki, Fumio

L4 ANSWER 84 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of uracil derivatives by reduction and amidation
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
PY 1997
2006
IN Miwa, Keiichi; Ito, Katsuhiro; Kato, Nobuyuki; Kuge, Yukyasu; Kasai, Masaji; Tomioka, Shinji

L4 ANSWER 85 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of xanthine derivatives for treatment of Parkinson's disease
SO U.S., 61 pp. Cont.-in-part of U.S. Ser. No. 42,535, abandoned.
CODEN: USXXAM
PY 1996
1994
1997
1996
IN Suzuki, Fumio; Shimada, Junichi; Koike, Nobuaki; Nakamura, Joji; Shioazaki, Shizuo; Ichikawa, Shunji; Ishii, Akio; Nonaka, Hiromi

L4 ANSWER 86 OF 87 CAPLUS COPYRIGHT 2007 ACS on STN
TI preparation of xanthine derivatives as antidepressants
SO PCT Int. Appl., 173 pp.
CODEN: PIXXD2
PY 1994
1994
2002
1999

```
     2002
     2002
     2002
     2003
     1996
     1994
IN   Suzuki, Fumio; Shimada, Junichi; Ishii, Akio; Nakamura, Joji; Ichikawa,
     Shunji; Kitamura, Shigeto; Koike, Nobuaki

L4   ANSWER 87 OF 87  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Therapeutic agents for Parkinson's disease
SO   Eur. Pat. Appl., 82 pp.
     CODEN: EPXXDW
PY   1994
     1999
     1994
     2000
     1994
     1999
     2000
     2000
     2000
     2000
IN   Suzuki, Fumio; Shimada, Junichi; Koike, Nobuaki; Nakamura, Joji; Shiozaki,
     Shizuo; Ichikawa, Shunji; Nonaka, Hiromi


=> d his

     (FILE 'HOME' ENTERED AT 15:21:43 ON 12 OCT 2007)

     FILE 'REGISTRY' ENTERED AT 15:21:52 ON 12 OCT 2007
L1              STRUCTURE UPLOADED
L2            0 S L1 SAM FAM
L3           12 S L1 FAM FULL

     FILE 'CAPLUS' ENTERED AT 15:22:32 ON 12 OCT 2007
L4           87 S L3

=> s anxiety or posttraumatic(a)stress
         17878 ANXIETY
            49 ANXIETIES
         17914 ANXIETY
                 (ANXIETY OR ANXIETIES)
          1346 POSTTRAUMATIC
        552547 STRESS
         98128 STRESSES
        591748 STRESS
                 (STRESS OR STRESSES)
           537 POSTTRAUMATIC(A)STRESS
L5       18282 ANXIETY OR POSTTRAUMATIC(A)STRESS

=> s l4 and l5
L6            1 L4 AND L5

=>
```

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 13:23:17 ON 12 OCT 2007

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:23:26 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 OCT 2007  HIGHEST RN 950420-07-2
DICTIONARY FILE UPDATES:  11 OCT 2007  HIGHEST RN 950420-07-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\553250.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:24:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     5924 TO ITERATE

 33.8% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       113865 TO   123095
PROJECTED ANSWERS:            4783 TO     6827

L2           50 SEA SSS SAM L1
```

=> s l1 sss full
FULL SEARCH INITIATED 13:24:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 119488 TO ITERATE

100.0% PROCESSED 119488 ITERATIONS 5419 ANSWERS
SEARCH TIME: 00.00.04

L3 5419 SEA SSS FUL L1

=> d scan

L3 5419 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C29 H38 N6 O3 . 2 C11 H8 O3 . 21/2 H2 O

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 5419 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Purine-2,6-dione, 3,9-dihydro-1,3-dimethyl-8-[[4-(phenylmethyl)-1-piperidinyl]methyl]-
MF C20 H25 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

```
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   173.45     173.66

FILE 'CAPLUS' ENTERED AT 13:25:34 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 12 Oct 2007  VOL 147 ISS 17
FILE LAST UPDATED: 11 Oct 2007  (20071011/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4         1502 L3

=> s anxiety or posttraumatic(a)stress(a)disorder or panic(a)disorder
          17878 ANXIETY
             49 ANXIETIES
          17914 ANXIETY
                  (ANXIETY OR ANXIETIES)
           1346 POSTTRAUMATIC
         552547 STRESS
          98128 STRESSES
         591748 STRESS
                  (STRESS OR STRESSES)
         264989 DISORDER
         210155 DISORDERS
         422688 DISORDER
                  (DISORDER OR DISORDERS)
            499 POSTTRAUMATIC(A)STRESS(A)DISORDER
           2610 PANIC
              3 PANICS
           2611 PANIC
                  (PANIC OR PANICS)
         264989 DISORDER
         210155 DISORDERS
         422688 DISORDER
                  (DISORDER OR DISORDERS)
           1880 PANIC(A)DISORDER
L5        18395 ANXIETY OR POSTTRAUMATIC(A)STRESS(A)DISORDER OR PANIC(A)DISORDER

=> s l4 and l5
L6            7 L4 AND L5
```

=> d ti au ab so py 1-7

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Combinations comprising PPAR agonists
IN Maher, William; Mercuri, Michele; Nevatia, Meenakshi; Chen, Hong; Wang, Pei-Ran
AB The present invention relates to a pharmaceutical composition comprising a PPAR agonist, or pharmaceutically acceptable salts thereof, alone or in combination with at least one active ingredient selected from the group consisting of (i) HDL increasing compds.; (ii) antidiabetics; (iii) an antihypertensive agent; (iv) cholesterol absorption modulator; (v) apo-A1 analogs and mimetics; (vi) renin inhibitors; (vii) thrombin inhibitors; (viii) aldosterone inhibitors; (ix) GLP-1 agonists; (x) glucagon receptor antagonists; (xi) cannabinoid receptor 1 antagonists; (xii) antiobesity agents; and (xiii) inhibitors of platelet aggregation or, in each case, a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable carrier. The pharmaceutical composition may be employed for the treatment of addictions (for example, nicotine and cocaine), dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, stroke, intermittent claudication, restenosis after PCTA, hypertension, obesity including reduction in CV risk in obese patients, inflammation, arthritis, cancer including breast, colon and prostate cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, IBDs (irritable bowel disease), Crohn's disease, hypofibrinolysis, hypercoaguable state, metabolic/cardiometabolic syndrome, elevated CRP, appearance of microalbuminuria, reduction of proteinuria, renal failure (DM, non-DM), NASH (non alc. steato-hepatitis) non-alc. fatty liver, CV events in patients with high CRP, vascular dementia, psoriasis, ischemia reperfusion injury, asthma, COPD, eosinophilia, RA, airway hyperresponsiveness (AHR), inflammatory digestive diseases (e.g., ulcerative colitis), and diseases of antigen-induced inflammatory responses. The compds. of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions such as impaired glucose tolerance, hyperglycemia, insulin resistance, type-1 and type-2 diabetes and Syndrome X. Also contemplated is the administration of the combinations of the present invention for the improvement of cardiac metabolism and cardioprotection in heart transplant patients, to facilitate smoking cessation or reduction and to prevent or treat conditions associated with smoking.
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
PY 2006
2006
2006
2007
2007
2007

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Synergy of dopamine D2 and adenosine A2 receptors activates protein kinase A (PKA) signaling via β/γ dimers, and use in the treatment of drug abuse and drug withdrawal
IN Gordon, Adrienne S.; Diamond, Ivan F.; Yao, Lina
AB The invention pertains to the discovery that a dopamine receptor agonist can activate PKA signaling and/or can act synergistically with an adenosine receptor to activate such signaling. In various embodiments, the invention exploits the synergy between the dopamine receptor pathway and an adenosine receptor pathway to provide methods of mitigating one or more symptoms produced by the chronic consumption of a substance of abuse or to mitigate one or more physiol. and/or behavioral symptoms associated with cessation of chronic consumption of a substance of abuse. In certain

embodiments, the methods involve administering to a mammal an effective amount of an adenosine receptor antagonist and an effective amount of a dopamine receptor antagonist, where the effective amount of the adenosine receptor antagonist is lower than the effective amount of an adenosine receptor antagonist administered without the dopamine receptor antagonist.

SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2

PY 2003
2004
2003

L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

TI The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A2A adenosine receptor antagonists

AU El Yacoubi, Malika; Ledent, Catherine; Parmentier, Marc; Costentin, Jean; Vaugeois, Jean-Marie

AB The elevated plus-maze and the light/dark box are two established anxiety tests in rodents, which are useful to screen putative anxiogenic effects of drugs. Caffeine is well known to promote anxious behavior in humans and animal models, but the precise site of action of the drug is still a matter of debate. The present study investigated whether the anxiogenic effects of caffeine observed in mice depend on the blockade of A2A receptor. First, the effects induced by the non-selective drug caffeine were compared with those elicited by two selective A2A receptor antagonists over a wide range of doses in the same exptl. conditions. The effects of A2A or A1 adenosine receptor agonists and of a selective A1 adenosine receptor antagonist were also investigated. Second, wild-type and A2A receptor knockout mice offered another approach to delineate the role played by A2A receptor in caffeine's anxiogenic effects. Mice were exposed to the elevated plus-maze or to the light/dark box for 5 min after acute or chronic administration of tested drugs. Caffeine acutely administered (50 or 100 mg/kg IP) induced anxiety -like effects in both procedures. Its chronic administration (50 mg/kg IP twice daily) for 1 wk or consumption in the drinking water (0.3 g/l) for 8 days or 2 mo were also anxiogenic in the plus-maze test. The A2A receptor antagonists ZM241385 (up to 60 mg/kg IP) and SCH58261 (up to 10 mg/kg IP) were devoid of acute effects in both tests. One week administration of ZM241385 (30 mg/kg IP) or SCH58261 (3 mg/kg IP) had no effects in the plus-maze test. An antagonist (DPCPX) and an agonist (CPA) at A1 receptors had no acute effects on anxiety-related indexes, whereas an A2A receptor agonist (CGS 21680) displayed non-specific motor effects in the plus-maze test. Acute administration of caffeine (50 mg/kg IP) induced no clear-cut anxiety-like effects in the plus-maze test in A2A receptor knockout mice that exhibited higher basal anxiety levels than wild-type mice. Chronic administration (50 mg/kg IP twice daily) for 1 wk elicited less anxiety-like behavior in A2A receptor knockout than in wild-type mice. Adaptative mechanisms following mutation in A2A receptors or their long-term blockade after chronic ingestion of caffeine may be responsible for increase proneness to anxiety. However, the short-term anxiety -like effect of caffeine in mice might not be related solely to the blockade of adenosine A2A receptors, since it is not shared by A2A selective antagonists.

SO Psychopharmacology (Berlin) (2000), 148(2), 153-163
CODEN: PSCHDL; ISSN: 0033-3158

PY 2000

L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

TI The Effects of Adenosine Ligands R-PIA and CPT on Ethanol Withdrawal

AU Gatch, M. B.; Wallis, C. J.; Lal, H.

AB The potential anxiogenic or anxiolytic effects of R(-)-N6-(2-phenylisopropyl)adenosine (R-PIA), an adenosine agonist, and 8-cyclopentyl-1,3,dimethylxanthine (CPT), an adenosine antagonist, were

tested during chronic exposure to ethanol and to ethanol-induced withdrawal in rats. Effects on anxiety were measured by the elevated plus maze and dark-light box. Ethanol consumption and preference was tested in an addnl. experiment In testing of elevated plus maze performance during withdrawal from ethanol, R-PIA produced no change in the anxiety-related behaviors of total arm entries and percent open arm entries, but produced a significant decrease in percent open arm time. CPT produced at least partial recovery from the anxiogenic effects of ethanol withdrawal on all three measures of elevated plus maze performance, although peak effects were seen at the intermediate dose of CPT (0.08 mg/kg) for total arm entries and percent open arm time. CPT also showed anxiolytic effects at low to intermediate doses (0.04, 0.08 mg/kg) in the dark-light box. CPT did not reduce the preference for ethanol over water or the total consumption of ethanol over a range of ethanol doses. In summary, the adenosine agonist, R-PIA, exacerbated the effects of ethanol withdrawal, whereas the adenosine antagonist, CPT, at least partially blocked the anxiogenic effects produced by ethanol withdrawal. These results suggest that adenosine antagonists, at least at some doses, may be useful for ameliorating the anxiogenic effects produced by ethanol withdrawal, although it does not appear useful for reducing consumption.

SO Alcohol (New York) (1999), 19(1), 9-14
CODEN: ALCOEX; ISSN: 0741-8329
PY 1999

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Adenosine A1 receptors modulate anxiety in CD1 mice
AU Florio, Chiara; Prezioso, Anita; Papaioannou, Aristotele; Vertua, Rodolfo
AB The effect of the selective adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) was investigated in CD1 mice by the elevated plus-maze and the light/dark test, two models for measuring anxiety in rodents. CCPA, administered i.p., had an anxiolytic effect at 0.3 nmol/kg in the elevated plus-maze and at 1 nmol/kg in the light/dark test. Brain levels of 22 nM were found after administration of 100 nmol/kg CCPA, as measured by ex vivo binding expts. These values are consistent with the occupancy of adenosine A1 but not A2 receptors by CCPA, and suggest that the anxiolytic-like action of CCPA may be mediated by centrally located adenosine A1 receptors. Both CPT, a selective adenosine A1 receptor antagonist, and IBMX, a non-selective adenosine antagonist, had an anxiogenic effect in the two tests. It is thus possible that purinergic neurons may be involved in the tonic modulation of affective state in mice.

SO Psychopharmacology (Berlin) (1998), 136(4), 311-319
CODEN: PSCHDL; ISSN: 0033-3158
PY 1998

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors
AU Imaizumi, Masahiro; Miyazaki, Shuichi; Onodera, Kenji
AB We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. All antagonists decreased the time spent in the light zone in this test, which suggested that these compds. have anxiogenic effects. The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. However, the antagonism of the theophylline-induced anxiogenic effects by CGS 21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. Finally, it is notable that xanthine-derived adenosine antagonists tested here commonly showed anxiogenic effects in the light/dark test in mice. It is suggested that there is a minor contribution of adenosine receptors to these effects, although theophylline-induced anxiogenic effects were

antagonized by an A2 receptor agonist.
SO Methods and Findings in Experimental and Clinical Pharmacology (1994), 16(9), 639-44
CODEN: MFEPDX; ISSN: 0379-0355
PY 1994

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI 8-Substituted theophyllines for alleviating anxiety in mammals
IN Stein, Herman Hal; Goodsell, Elizabeth
AB The title substituted theophyllines (I, R=Me, Et, Pr, iso-Pr, pentyl, cyclopentyl, hexyl), useful in the treatment of depression were prepared from 5,6-diamino-1,3-dimethyluracil and an acid RCO2H (Hager, et al., CA 49: 3179d).
SO U.S., 3 pp.
CODEN: USXXAM
PY 1971

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.22	207.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.46	-5.46

FILE 'REGISTRY' ENTERED AT 13:28:35 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 OCT 2007 HIGHEST RN 950420-07-2
DICTIONARY FILE UPDATES: 11 OCT 2007 HIGHEST RN 950420-07-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\xanthine.str

L7 STRUCTURE UPLOADED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	208.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE 0.00 -5.46

FILE 'CAPLUS' ENTERED AT 13:29:03 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Oct 2007 VOL 147 ISS 17
FILE LAST UPDATED: 11 Oct 2007 (20071011/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l7 sss sam
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 13:29:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4 TO 200
PROJECTED ANSWERS: 1 TO 80

L8 1 SEA SSS SAM L7

L9 1 L8

=> d ti au abs so py

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
TI Myocardial adenosine A2a receptor imaging of rabbit by PET with [11C]KF17837
AU Ishiwata, Kiichi; Sakiyama, Yojiro; Sakiyama, Takayo; Shimada, Junichi; Toyama, Hinako; Oda, Keiichi; Suzuki, Fumio; Senda, Michio
AB Adenosine A2a receptors are found in the endothelia, vascular smooth muscle cells and cardiac myocytes. The properties of a carbon-11-labeled A2a antagonist [11C]KF17837 for myocardial imaging were evaluated by dynamic PET scanning of the myocardium in rabbits. Myocardial uptake of [11C]KF17837 was clearly visualized by PET. The tracer was taken up at a

high level by the myocardium immediately after the injection, and the myocardial level of radioactivity gradually decreased. On the other hand, an inactive [11C]Z-isomer of [11C]KF17837 showed a very low myocardial uptake and the myocardium was not visualized with a selective A1 antagonist [11C]KF15372. By co-injection with carrier KF17837 or a xanthine type A2a antagonist 7-chlorostyrylcaffeine (CSC), the myocardial uptake of [11C]KF17837 was completely blocked. The effect of non-xanthine A2a antagonists ZM 241385 and SCH 58261, which have a higher affinity than CSC, was smaller than that of the CSC. The effect of weak antagonists caffeine and alloxazine or a xanthine type A1 antagonist KF15372 on the radioactivity level was small. It is concluded that PET with [11C]KF17837 can image myocardial adenosine A2a receptors.

SO Annals of Nuclear Medicine (1997), 11(3), 219-225
CODEN: ANMEEX; ISSN: 0914-7187

PY 1997

=> s l7 sss full
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 13:30:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 174 TO ITERATE

100.0% PROCESSED 174 ITERATIONS 52 ANSWERS
SEARCH TIME: 00.00.01

L10 52 SEA SSS FUL L7

L11 138 L10

=> d his

(FILE 'HOME' ENTERED AT 13:23:17 ON 12 OCT 2007)

FILE 'REGISTRY' ENTERED AT 13:23:26 ON 12 OCT 2007
L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 5419 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:25:34 ON 12 OCT 2007
L4 1502 S L3
L5 18395 S ANXIETY OR POSTTRAUMATIC(A)STRESS(A)DISORDER OR PANIC(A)DISOR
L6 7 S L4 AND L5

FILE 'REGISTRY' ENTERED AT 13:28:35 ON 12 OCT 2007
L7 STRUCTURE UPLOADED

FILE 'CAPLUS' ENTERED AT 13:29:03 ON 12 OCT 2007
S L7

FILE 'REGISTRY' ENTERED AT 13:29:14 ON 12 OCT 2007
L8 1 S L7 SSS SAM

FILE 'CAPLUS' ENTERED AT 13:29:14 ON 12 OCT 2007
L9 1 S L8 SSS SAM
S L7

```
     FILE 'REGISTRY' ENTERED AT 13:30:00 ON 12 OCT 2007
L10           52 S L7 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:30:01 ON 12 OCT 2007
L11          138 S L10 SSS FULL

=> s l5 and l11
L12            1 L5 AND L11

=> d ti

L12  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   A method using an adenosine A2A receptor antagonist for treating an
     anxiety disorder


=> s ti au abs so py
        363566 TI
          1263 TIS
        364505 TI
                  (TI OR TIS)
        188587 AU
          1358 AUS
        189862 AU
                  (AU OR AUS)
        238189 ABS
        733989 SO
          5911 SOS
        739672 SO
                  (SO OR SOS)
         16446 PY
           695 PIES
         17140 PY
                  (PY OR PIES)
L13          0 TI AU ABS SO PY
                  (TI(W)AU(W)ABS(W)SO(W)PY)

=> d ti au abs so py
L13 HAS NO ANSWERS
L13           0 SEA FILE=CAPLUS ABB=ON  PLU=ON  TI AU ABS SO PY


=> d ti au abs so py l12

L12  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   A method using an adenosine A2A receptor antagonist for treating an
     anxiety disorder
IN   Kase, Hiroshi; Seno, Naoki; Shiozaki, Shizuo; Kobayashi, Minoru; Kase,
     Junya
AB   Anxiety disorders, such as panic disorder,
     agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic
     stress disorder, generalized anxiety disorder, specific phobia,
     or the like, are treated by administering an effective amount of at least
     one adenosine A2A receptor antagonist (e.g. a xanthine derivative) to a
     patient in need thereof, optionally in combination with an anxiolytic(s)
     other than the adenosine A2A receptor antagonist.
SO   PCT Int. Appl., 96 pp.
     CODEN: PIXXD2
PY   2004
     2004
     2004
     2006
     2006
```

2006
2006
2006
2006
2005
2007

=>

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 11:41:15 ON 12 OCT 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.84       0.84

FILE 'REGISTRY' ENTERED AT 11:43:43 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   11 OCT 2007  HIGHEST RN 950420-07-2
DICTIONARY FILE UPDATES:  11 OCT 2007  HIGHEST RN 950420-07-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\xanthin1.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:44:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     5478 TO ITERATE
```

36.5% PROCESSED 2000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 105122 TO 113998
PROJECTED ANSWERS: 3053 TO 4725

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[[3-(aminomethyl)phenyl]methyl]-3-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)- (9CI)
MF C30 H40 N6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Purine-2,6-dione, 1-butyl-3,7-dihydro-8-phenyl- (9CI)
MF C15 H16 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full
FULL SEARCH INITIATED 11:45:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 110331 TO ITERATE

100.0% PROCESSED 110331 ITERATIONS 3427 ANSWERS
SEARCH TIME: 00.00.03

L3 3427 SEA SSS FUL L1

=> d scan

L3 3427 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[5-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-2-pyridinyl]-, ethyl ester (9CI)
MF C23 H27 N7 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 3427 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C18 H19 Cl F N7 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.45	174.29

FILE 'CAPLUS' ENTERED AT 11:46:18 ON 12 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Oct 2007 VOL 147 ISS 17
FILE LAST UPDATED: 11 Oct 2007 (20071011/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3
L4         1336 L3

=> s anxiety
          17878 ANXIETY
             49 ANXIETIES
L5        17914 ANXIETY
                (ANXIETY OR ANXIETIES)

=> s l4 and l5
L6            6 L4 AND L5

=> d ti au abs so py 1-6

L6   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Synergy of dopamine D2 and adenosine A2 receptors activates protein kinase
     A (PKA) signaling via β/γ dimers, and use in the treatment of
     drug abuse and drug withdrawal
IN   Gordon, Adrienne S.; Diamond, Ivan F.; Yao, Lina
AB   The invention pertains to the discovery that a dopamine receptor agonist
     can activate PKA signaling and/or can act synergistically with an
     adenosine receptor to activate such signaling.  In various embodiments,
     the invention exploits the synergy between the dopamine receptor pathway
     and an adenosine receptor pathway to provide methods of mitigating one or
     more symptoms produced by the chronic consumption of a substance of abuse
     or to mitigate one or more physiol. and/or behavioral symptoms associated
     with cessation of chronic consumption of a substance of abuse.  In certain
     embodiments, the methods involve administering to a mammal an effective
     amount of an adenosine receptor antagonist and an effective amount of a
     dopamine receptor antagonist, where the effective amount of the adenosine
     receptor antagonist is lower than the effective amount of an adenosine
     receptor antagonist administered without the dopamine receptor antagonist.
SO   PCT Int. Appl., 152 pp.
     CODEN: PIXXD2
PY   2003
     2004
```

2003

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A2A adenosine receptor antagonists
AU El Yacoubi, Malika; Ledent, Catherine; Parmentier, Marc; Costentin, Jean; Vaugeois, Jean-Marie
AB The elevated plus-maze and the light/dark box are two established anxiety tests in rodents, which are useful to screen putative anxiogenic effects of drugs. Caffeine is well known to promote anxious behavior in humans and animal models, but the precise site of action of the drug is still a matter of debate. The present study investigated whether the anxiogenic effects of caffeine observed in mice depend on the blockade of A2A receptor. First, the effects induced by the non-selective drug caffeine were compared with those elicited by two selective A2A receptor antagonists over a wide range of doses in the same exptl. conditions. The effects of A2A or A1 adenosine receptor agonists and of a selective A1 adenosine receptor antagonist were also investigated. Second, wild-type and A2A receptor knockout mice offered another approach to delineate the role played by A2A receptor in caffeine's anxiogenic effects. Mice were exposed to the elevated plus-maze or to the light/dark box for 5 min after acute or chronic administration of tested drugs. Caffeine acutely administered (50 or 100 mg/kg IP) induced anxiety -like effects in both procedures. Its chronic administration (50 mg/kg IP twice daily) for 1 wk or consumption in the drinking water (0.3 g/l) for 8 days or 2 mo were also anxiogenic in the plus-maze test. The A2A receptor antagonists ZM241385 (up to 60 mg/kg IP) and SCH58261 (up to 10 mg/kg IP) were devoid of acute effects in both tests. One week administration of ZM241385 (30 mg/kg IP) or SCH58261 (3 mg/kg IP) had no effects in the plus-maze test. An antagonist (DPCPX) and an agonist (CPA) at A1 receptors had no acute effects on anxiety-related indexes, whereas an A2A receptor agonist (CGS 21680) displayed non-specific motor effects in the plus-maze test. Acute administration of caffeine (50 mg/kg IP) induced no clear-cut anxiety-like effects in the plus-maze test in A2A receptor knockout mice that exhibited higher basal anxiety levels than wild-type mice. Chronic administration (50 mg/kg IP twice daily) for 1 wk elicited less anxiety-like behavior in A2A receptor knockout than in wild-type mice. Adaptative mechanisms following mutation in A2A receptors or their long-term blockade after chronic ingestion of caffeine may be responsible for increase proneness to anxiety. However, the short-term anxiety -like effect of caffeine in mice might not be related solely to the blockade of adenosine A2A receptors, since it is not shared by A2A selective antagonists.
SO Psychopharmacology (Berlin) (2000), 148(2), 153-163
CODEN: PSCHDL; ISSN: 0033-3158
PY 2000

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI The Effects of Adenosine Ligands R-PIA and CPT on Ethanol Withdrawal
AU Gatch, M. B.; Wallis, C. J.; Lal, H.
AB The potential anxiogenic or anxiolytic effects of R(-)-N6-(2-phenylisopropyl)adenosine (R-PIA), an adenosine agonist, and 8-cyclopentyl-1,3,dimethylxanthine (CPT), an adenosine antagonist, were tested during chronic exposure to ethanol and to ethanol-induced withdrawal in rats. Effects on anxiety were measured by the elevated plus maze and dark-light box. Ethanol consumption and preference was tested in an addnl. experiment In testing of elevated plus maze performance during withdrawal from ethanol, R-PIA produced no change in the anxiety-related behaviors of total arm entries and percent open arm entries, but produced a significant decrease in percent open arm time. CPT produced at least partial recovery from the anxiogenic effects of ethanol withdrawal on all three measures of elevated plus maze

performance, although peak effects were seen at the intermediate dose of CPT (0.08 mg/kg) for total arm entries and percent open arm time. CPT also showed anxiolytic effects at low to intermediate doses (0.04, 0.08 mg/kg) in the dark-light box. CPT did not reduce the preference for ethanol over water or the total consumption of ethanol over a range of ethanol doses. In summary, the adenosine agonist, R-PIA, exacerbated the effects of ethanol withdrawal, whereas the adenosine antagonist, CPT, at least partially blocked the anxiogenic effects produced by ethanol withdrawal. These results suggest that adenosine antagonists, at least at some doses, may be useful for ameliorating the anxiogenic effects produced by ethanol withdrawal, although it does not appear useful for reducing consumption.

SO Alcohol (New York) (1999), 19(1), 9-14
CODEN: ALCOEX; ISSN: 0741-8329

PY 1999

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

TI Adenosine A1 receptors modulate anxiety in CD1 mice

AU Florio, Chiara; Prezioso, Anita; Papaioannou, Aristotele; Vertua, Rodolfo

AB The effect of the selective adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA) was investigated in CD1 mice by the elevated plus-maze and the light/dark test, two models for measuring anxiety in rodents. CCPA, administered i.p., had an anxiolytic effect at 0.3 nmol/kg in the elevated plus-maze and at 1 nmol/kg in the light/dark test. Brain levels of 22 nM were found after administration of 100 nmol/kg CCPA, as measured by ex vivo binding expts. These values are consistent with the occupancy of adenosine A1 but not A2 receptors by CCPA, and suggest that the anxiolytic-like action of CCPA may be mediated by centrally located adenosine A1 receptors. Both CPT, a selective adenosine A1 receptor antagonist, and IBMX, a non-selective adenosine antagonist, had an anxiogenic effect in the two tests. It is thus possible that purinergic neurons may be involved in the tonic modulation of affective state in mice.

SO Psychopharmacology (Berlin) (1998), 136(4), 311-319
CODEN: PSCHDL; ISSN: 0033-3158

PY 1998

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

TI Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors

AU Imaizumi, Masahiro; Miyazaki, Shuichi; Onodera, Kenji

AB We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. All antagonists decreased the time spent in the light zone in this test, which suggested that these compds. have anxiogenic effects. The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. However, the antagonism of the theophylline-induced anxiogenic effects by CGS 21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. Finally, it is notable that xanthine-derived adenosine antagonists tested here commonly showed anxiogenic effects in the light/dark test in mice. It is suggested that there is a minor contribution of adenosine receptors to these effects, although theophylline-induced anxiogenic effects were antagonized by an A2 receptor agonist.

SO Methods and Findings in Experimental and Clinical Pharmacology (1994), 16(9), 639-44
CODEN: MFEPDX; ISSN: 0379-0355

PY 1994

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

TI 8-Substituted theophyllines for alleviating anxiety in mammals

IN Stein, Herman Hal; Goodsell, Elizabeth

```
GI   For diagram(s), see printed CA Issue.
AB   The title substituted theophyllines (I, R=Me, Et, Pr, iso-Pr, pentyl,
     cyclopentyl, hexyl), useful in the treatment of depression were prepared
     from 5,6-diamino-1,3-dimethyluracil and an acid RCO2H (Hager, et al., CA
     49: 3179d).
SO   U.S., 3 pp.
     CODEN: USXXAM
PY   1971


=> s generalized(a)anxiety(a)disorder
         86657 GENERALIZED
             1 GENERALIZEDS
         86657 GENERALIZED
                 (GENERALIZED OR GENERALIZEDS)
         17878 ANXIETY
            49 ANXIETIES
         17914 ANXIETY
                 (ANXIETY OR ANXIETIES)
        264989 DISORDER
        210155 DISORDERS
        422688 DISORDER
                 (DISORDER OR DISORDERS)
L7         420 GENERALIZED(A)ANXIETY(A)DISORDER

=> d his

     (FILE 'HOME' ENTERED AT 11:41:15 ON 12 OCT 2007)

     FILE 'REGISTRY' ENTERED AT 11:43:43 ON 12 OCT 2007
L1               STRUCTURE UPLOADED
L2            50 S L1 SSS SAM
L3          3427 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:46:18 ON 12 OCT 2007
L4          1336 S L3
L5         17914 S ANXIETY
L6             6 S L4 AND L5
L7           420 S GENERALIZED(A)ANXIETY(A)DISORDER

=> s l4 and l7
L8             0 L4 AND L7

=>
```